New cocktail of immune drugs and chemo takes on deadly mesothelioma
NCT ID NCT07514793
First seen Apr 12, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This phase 2 trial tests a combination of two immune-boosting drugs (iparomlimab and tovorilimab) plus bevacizumab and standard chemotherapy as a first treatment for advanced mesothelioma. The study will enroll 37 adults who have not had prior therapy. Researchers will measure how many patients' tumors shrink or stabilize, and track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan university cancer hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab and tovorilimab (immune-boosting drugs) plus bevacizumab (anti-angiogenic drug) and chemotherapy (pemetrexed and cisplatin or carboplatin)
What this could lead to
If successful, this combination could offer a new first-line treatment option that shrinks tumors or slows disease progression in advanced mesothelioma.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 37 participants, so results may not apply broadly. The drug combination may cause significant side effects, and there is no guarantee it will work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.